Credence Genomics

Executive Summary

Credence Genomics, a South Korean biotech founded in 2020, is commercializing next‑generation sequencing (NGS)‑based pathogen detection platforms. Its proprietary AIoS™ and MMR™ technologies enable rapid, high‑precision identification of bacteria, fungi, and viruses while providing antimicrobial‑resistance insights. The company addresses the critical need for faster, more accurate infectious disease diagnostics, particularly in the context of rising antimicrobial resistance (AMR). By combining NGS with artificial intelligence, Credence Genomics reduces turnaround time from days to hours, supporting clinical decision‑making. With a commercial‑stage status and a small, focused team of 10‑50 employees, the company has established a foothold in the South Korean healthcare market and is poised for regional expansion. The global push for rapid diagnostics and AMR management presents a significant opportunity for Credence Genomics. As healthcare systems seek to combat infectious diseases more effectively, the demand for advanced molecular diagnostics is accelerating. The company’s technology platform can be deployed in hospital labs, reference labs, and public health settings. While specific funding and valuation details are not yet public, the company’s operational maturity suggests a solid foundation. Future growth will likely hinge on geographic expansion, strategic partnerships, and securing regulatory approvals beyond South Korea. Credence Genomics is well‑positioned to capture value in the rapidly evolving precision diagnostics landscape.

Upcoming Catalysts (preview)

• Q3 2026CE‑IVDR certification for NGS platform60% success
• Q4 2026Partnership with major South Korean hospital network70% success
• Q2 2027Series A funding round50% success